Remove Compliance Remove Genetic Engineering Remove Protein
article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

Specialty enzymes are proteins that can act as very specific biocatalysts to accelerate reactions and produce the desired target molecule in pharmaceuticals,” explains Kristoffer Laursen, Head of R&D at Novo Nordisk Pharmatech. “In In the evolving biotechnology industry, enzymes are important process aids.

Drugs 295
article thumbnail

mRNA Cancer Vaccines and Therapies: An Overview

Advarra

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. The mRNA constructs used in COVID-19 vaccines, for example, direct cells to produce a version of the “spike” protein studding the surface of SARS-CoV-2.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How Potential Changes to the NIH Guidelines Could Impact IBC Review

WCG Clinical

This change expanded the definition of HGT research to include research using nucleic acids that are able to replicate, be transcribed, translated into protein, and/or integrate into the host genome. Since then, however, certain genetic engineering technologies (e.g.,

Genome 52
article thumbnail

The New Frontier in Drug Development: Understanding Biologics and Small Molecules

Cloudbyz

Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells. Mode of Action : Small Molecules: They often work by binding to specific sites on target proteins to inhibit or activate their function, which can affect various biological pathways inside the cell.

article thumbnail

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

The Pharma Data

Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S.